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SUMMARY
A significant percentage survival, representing a large numberofviable cells, can
occur in a Staphylococcus aureus population exposed to concentrations of
mupirocin up to 1,000 times the minimum inhibitory concentration. An elevated
ratio ofminimum inhibitory to minimum bactericidal concentration ofmupirocin
with staphylococci was recorded. Staphylococci which survive exposure to
mupirocin may be less sensitive to the subsequent bactericidal action of the
antibiotic. The observations may explain the re -colonisation with staphylococci
seen in some studies.
INTRODUCTION
The predominant reservoir of Staphylococcus aureus is man: about 15-35%
of the population are colonised with S aureus in the anterior nares from which
the organism can readily be disseminated to other parts of the body and to the
environment. A decrease in host resistance to infection with S aureus can be
associated with a wide variety of clinical syndromes of differing severity. The
management of these infections may be complicated when multi -resistant
-staphylococci are encountered. Although the occurrence of multiple-antibiotic
resistant strains of S aureus is still only about 5%, they can cause serious
problems 1,2 especially in association with hospital special care units where the
opportunities for cross-infection and emergence of multiple resistance are high.
Any infection control policy aimed at reducing the incidence of staphylococcal
infections due to multiple resistant strains must include attempts to eradicate
nasal carriage. The topical use of antibiotics or skin disinfectants has had variable
success, is unreliable, and may have inherent disadvantages in respect of
resistance development.3 Resistance to chlorhexidine, commonly used as a
topical agent to reduce staphylococcal carriage, has recently been reported.4
A new compound, mupirocin (derived from Pseudomonas fluorescens, pseudo-
monic acid) has been shown to be effective in the eradication of S aureus from
the anterior nares5,6 and the skin7,8 when applied as a 2 % ointment. Casewell
and Hill9 have also shown that in vitro mupirocin behaves as a bactericidal
antibiotic giving 99.9% reduction in the number of viable staphylococci within
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24 hours' exposure. The aim of this study was to investigate the effect on
staphylococci of various concentrations of mupirocin at differing inoculum
concentrationsand at different stagesofgrowth and toexamine thecharacteristics
of surviving bacteria.
MATERIALS AND METHODS
Mupirocin (Beecham Pharmaceuticals, Worthing) was supplied in pellet form as
the sodium salt. Each pellet, weighing 20.5mg, was dissolved in distilled water to
give the appropriate antibiotic concentration, sterilised by filtration (0.224,
Millipore UK) and used on the day of preparation.
Eighteen clinical isolates of S aureus were examined, in addition to two type
cultures, S aureus (NCTC 6571) and a methicillin resistant S aureus (NCTC
10442). All strains were grown on nutrient agar slopes for 24 hours at 370C,
stored at 40C and sub-cultured weekly. Mueller-Hinton (M-H) agar (CM 337),
blood agar (Gibco 152
-0600) containing 5% (v/v) defibrinated horse blood, and
quarter-strength Ringer's solution (Oxoid BR 52) were prepared according to the
manufacturer's instructions. Nutrient agar slopes (Oxoid R2) were supplied by
the manufacturer.
Minimum inhibitory concentrations were carried out using the agar incorporation
method. Four-hour peptone water cultures were used as inocula, and dispensed
using a multipoint inoculator (Denley Instruments, Ltd) on to M-H agar plates
containing two-fold serial dilutionsof mupirocin. Inoculated plateswereincubated
aerobically at 37°C and examined for growth after 24 hours. The lowest
concentration which gave a complete absence of growth was recorded as the
minimum inhibitory concentration. Drug-free plates were inoculated as controls
and S aureus NCTC 6571 and S aureus NCTC 10442 were included in each test
set as control organisms.
Minimum bactericidal concentrations were determined using the velvet pad
transfer method. The surface of each agar plate used in the previous determin-
ations were sampled with a sterile velvet pad. The pad was then transferred on to
the surface of an M-H agar plate. Following incubation at 37°C for 48 hours the
minimum bactericidal concentration was calculated as the lowest concentration
of antibiotic yielding no growth after velvet pad sub-culture.
Viable bacterial counts were determined by the spread plate method using
quarter-strength Ringer's solution as diluent and 5 % blood agar as plating
medium. After incubation of plates at 370C, results were expressed as the
number of colony-forming units per ml of the bacterial suspension. To remove
mupirocin from bacterial suspensions prior to enumeration ofviable bacteria, unit
volumes of suspension were centrifuged at 3,000 rpm for five minutes, the
supernatant decanted, the cellular deposit washed once in -broth, and then
resuspended in broth to the original volume.
Staphylococci were grown in either M -H broth or quarter-strength Ringer's
solution in the presence or absence of specified concentrations of mupirocin.
Two inoculum levels were investigated, approximately 107 and 105 colony-
forming units per ml. Cultures were sampled at intervals during the incubation
period and viable counts performed. All experiments were carried outin triplicate.
The ability of S aureus to initiate growth in liquid medium after exposure to
mupirocin was measured by conductance using the 112L microbiological
growth analyser (Malthus Instruments, UK, Ltd). Staphylococci were exposed to
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mupirocin at a concentration of 256mg/I for different periods. The antibiotic was
removed from each sample by the methods described and 1ml of this suspension
was used to inoculate 9ml broth contained in 10ml capacity growth cells.
Identical cells containing antibiotic only or bacterial suspension only were
incorporated as controls. All tests were incubated at 37°C and performed in
duplicate. Changes in conductance of the growth medium due to bacterial growth
were monitored and recorded; conductance measurements were made in
microsiemens (ps). The interpretation of the conductance measurements in
relation to microbial growth were as described in detail by Baynes, Comrie and
Prain.'0 As growth proceeds, the conductivity of the medium increases, and a
growth curve can be plotted of time (hours) against conductivity (ps). To test the
stability of the mupirocin throughout each investigation, an aliquot of culture was
taken before and after completion of each experiment. Each aliquot was filter-
sterilised (0.22p) and divided into two portions. One portion was treated with
esterase in the ratio of one volume porcine liver esterase suspension (Sigma
Diagnostics E-3128) to one volume of test suspension for 30 minutes in a 37 °C
waterbath. The other portion was untreated. Both treated and untreated samples
were titrated in quarter -strength Ringer's solution (two-fold dilutions) beyond the
minimum inhibitory concentration of the organism used. Single drops of 25 pl of
each titration dilution were dispensed on to the surface of pre-dried blood agar
plates and allowed to absorb into the medium undisturbed. After absorption,
the plates were flooded with a log phase broth culture of S aureus NCTC 6571
incubated 18 hours at 37°C. Plates were examined for zones of clearing
indicating the presence of the antibiotic.
RESU(LTS
The survival of S aureus NCTC 6571 in M -H broth when exposed to concentrat-
ions of 2,16 and 256 mg/l mupirocin is shown in Fig 1. Using both high and low
inoculum levels it was shown that after an initial increase in viable count over
a three-hour period, a stationary phase of growth was established for a period
of 24 hours. Where the initial inoculum level was exposed to 16 or 256 mg/I
mupirocin, the viable count fell to less than 10 colony-forming units per ml,
representing at least a 99.9% reduction of viable cells. For cells exposed to
2mg/I mupirocin a 99.8% reduction in viable count was achieved. Where the
higher inoculum level was examined, there was a reduction in viable count of 0,
98 and 99.6% after exposure to concentration of 2, 16 and 256 mg/I mupirocin.
Under the conditions described with the higher inoculum level, reductions in
viable count of 98% and 99.6% corresponded to counts of surviving bacteria
after 120 hours' exposure to mupirocin of 2 x 105 and 4 x 104 colony-forming
units per ml respectively.
The survival kinetics for a further four strains ofS aureus showed a similar pattern
to that obtained for S aureus NCTC 6571. The influence of these inoculum sizes
on the percentage survival of three multiple -resistant (including methicillin
resistance) staphylococci and S aureus NCTC 10442 was studied after 64 hours'
continuous exposure to 256mg/1 mupirocin, and significant numbers of all
strains survived this exposure. A higher percentage survival was found with the
higher inoculum level. No significant difference in results was obtained with
inocula prepared from lag phase, logarithmic phase orstationary phase cells. The
effect of mupirocin (256mg/1) on the survival of staphylococci at different
inoculum levels in M -H broth and in quarter-strength Ringer's solution is shown
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Fig 1. The effectof mupirocin on the survival ofS aureus NCTC 6571 at two inoculum levels (1 x 107
colony-forming units per ml, black symbols; 1 x 105 colony-forming units per ml, open symbols).
in Fig 2. Cells grown in M-H broth alone (Fig 2B) demonstrated a normal growth
curve for uninhibited cells, whereas cells exposed to 256mg/I mupirocin in M-H
broth showed a stationary phase of growth established over 24 hours followed
by a decline in viable count. The decline in viable count shown in M-H broth
confirmed the effect of inoculum on the percentage survival after 24 hours' and
120 hours' exposure to mupirocin. The viability of cells in quarter-strength
Ringer's solution began to decline, even in the absence of mupirocin (Fig 2A).
This was most marked with the lower initial inoculum level. However, in the
presence of mupirocin, no surviving cells could be detected after 48 hours with
the lower initial inoculum level or after 120 hours with the higher initial inoculum
level.
A relationship wasestablished between the inoculum sizeofSaureus NCTC 6571
and time of detection of conductance change using the Malthus microbiological
growth analyser. The detection time varied between three hours and 15 hours for
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Fig 2. Survival ofSaureus NCTC 6571 at two different inoculum levels with and without concomitant
exposure to mupirocin at a concentration of 256mg/l. Both a non nutritional (quarter-strength
Ringer's solution - Fig 2A) and nutritional (M-H broth - Fig 2B) environment were tested. The
initial inoculum contained cells in a logarithmic phase of growth.
Inoculum levels: 1 x 107 colony-forming units per ml (black symbols), I x 105 colony-forming units
per ml (open symbols). Solid line with mupirocin, dotted line ----without mupirocin.
inocula varying from 2 x 109 to 2 x 102 colony-forming units per ml. S aureus
cells exposed to mupirocin (2mg/I, 16mg/I, or 256mg/1) for different periods
(24, 48 and 72 hours) showed no residual effect of mupirocin. In each case the
time of detection of conductance change was as expected from the calculated
viable count of mupirocin-exposed cells, and the pattern and magnitude of
conductance of cells pre-exposed to mupirocin was the same as the control
unexposed organism.
The minimum inhibitory and minimal bactericidal concentrations of mupirocin
were determined before and after treatment of S aureus cultures for 24 hours
with the same drug (Table). When the pre-treated cells were recovered on
antibiotic-free M-H agar after overnight incubation at 370C, no change in their
susceptibility to mupirocin was noted. The minimal bactericidal concentration
was generally four-fold higher than the minimal inhibitory concentration. When
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TABLE
The effect ofprevious exposure to mupirocin on the minimum inhibitory
concentrations (MIC) and minimal bactericidal concentration (MBC) ofmupirocin
on Staphylococcus aureus (18 clinical isolates, and two control cultures,
NCTC 6571 and 10442)
Study A * Study B Study C
Previous exposure Previous exposure No previous
with cells washed exposure
MIC MBC MIC MBC MIC MBC
18 clinical
isolates 0.5 2.0 0.13 64 0.5 2.0
(mean and
range) (0.25-64) (2-64) (0.03-32) (16-64) (0.25-64) (2-64)
2 control
cultures (mean) 0.4 2.0 0.03 64 0.4 2
*The previously exposed staphylococci had been grown in a medium containing 256mg/l mupirocin
for 24 hours; the cells were then grown on M - H agar for 16 hours without the antibiotic before further
inoculation (Study A), or simply washed free of the antibiotic (Study B). The cells in Study C had not
previously been exposed to mupirocin.
mupirocin-treated cells were washed to remove the antibiotic and used directly
as an inoculum, the minimal inhibitory concentration generally decreased
1 -2 fold; the bactericidal concentration however, exceeded the inhibitory
concentration by a factor of 500 for all clinical isolates and type cultures.
No variation in assays of mupirocin activity before and after each experiment was
found. This confirmed the stability of the antibiotic in the presence of both
quarter-strength Ringer's solution and M-H broth and at 37°C incubation.
Bacterial degradation ofthe antibiotic was not apparent even when broth cultures
were tested after several days' continuous incubation of 370C. Treatment of
culture filtrates with esterase negated the titration value in all cases, indicating the
continued presence of the antibiotic.
DISCUSSION
S aureus is one of the major causes (20%) of hospital infection "I which can
become life-threatening in debilitated patients.'2 The re-emergence of multiple-
resistant, including methicillin-resistant, staphylococci hasplaced further burdens
both on the patient and on hospital personnel with its associated problems in the
control of cross-infection.", 13 Such were these problems that recently detailed
guidelines for the prompt control and management of methicillin -resistant
S aureus infections were published by the Hospital Infection Society and British
Society for Antimicrobial Chemotherapy (1986). 14
Although staphylococci can be found associated with a wide range of hospital-
acquired infection from skin sepsis to endocarditis, the main reservoir for these
organisms is the anterior nares, and recently the importance of gastro -intestinal
carriage in hospitalised patients has been reported.'5 The problem of carriage of
S aureus has been reflected in the varied treatment regimens and measures used
to control or eliminate this carriage, often resulting in organisms becoming
antibiotic- resistant.3
©) The Ulster Medical Society, 1988.
55The Ulster Medical Journal
The new topical antibiotic mupirocin seems to satisfy a number of criteria
expected of a topical agent. It has a novel mode of action, selective anti-bacterial
activity, a total lack of cross-resistance to other antibiotics, and is metabolised
and excreted quickly as a non-toxic compound. Another favourable property is
its action against multiple-resistant coagulase-positive and coagulase-negative
staphylococci.9 White et al (1984) stated that using experimental inocula of 10 5
colony-forming units per ml, more than 99.9% of S aureus were killed in 24
hours.6 For a number ofstrains, using similar inoculum concentrations, Casewell
and Hill (1984)agreed withthisobservation, demonstrating thatat concentrations
of 16mg/I a 99.9% reduction in viable count was achieved by 24 hours and
sterility of the culture by 120 hours.9 In this study we found that with inoculum
levels of 105 to 107 colony-forming units per ml, a significant percentage
survival, representing a large number of viable cells, could occur in an S aureus
population exposed to concentrations of mupirocin up to 256mg/I (equivalent to
1,000 times the minimum inhibitory concentrations). This was demonstrated
with a number of strains, including methicillin -resistant S aureus.
Surviving cells, if transferred to an environment free of mupirocin, showed the
same growth characteristics as unexposed cells. With high inoculum levels, even
exposure to 256mg/I for 72 hours could be followed by a rapid recovery when
removed to an antibiotic-free environment.
A significant difference was noted between the effect of mupirocin in S aureus
grown in broth and in quarter-strength Ringer's solution. In quarter-strength
Ringer's solution, the slope of the curve for both exposed and non -exposed cells
werevery similar, suggesting a direct effectof the Ringer's environment. However,
no viable cells were recovered after 120 hours, when the initial population ofcells
were exposed to mupirocin (256mg/1) in a Ringer's salts environment; this
suggested that the action of the antibiotic was not altogether dependent on the
presence of bacteria in a phase of rapid growth and protein synthesis. This was
confirmed by the findings that the antibiotic effect on viable counts of bacteria
was not significantly different using lag, logarithmic or stationary phase cells. The
ratio of minimal inhibitory to minimal bactericidal concentration of mupirocin
with staphylococci is quoted at between 1:8 and 1:32. Our findings demonstrate
a ratio of at least 1:128 for cells that have been treated with mupirocin and used
directly as inoculum. It appears that cell growth in the presence of mupirocin
ceases and will only resume on removal of the antibiotic. The change in the ratio
in this case seems to confirm that cells surviving exposure to mupirocin at high
concentrations are less sensitive to the subsequent bactericidal action of
mupirocin. It is possible that in an in vitro situation the cells which survived an
initial challenge with high concentrations of mupirocin could be less sensitive to
the bactericidal action of subsequent exposure.
These results do not differ very much from the observations of other workers,
although with similar inocula we cannot demonstrate such a high percentage loss
of viability in the presence of mupirocin. This may be due to some carry-over of
mupirocin on plating media. Cells are sufficiently damaged to be inhibited from
rapid growth on solid media, but viability can often be demonstrated by velvet
pad transfer to fresh media or by prior centrifugation of treated organisms to
remove the antibiotic. At inoculum levels higher than 10 5 we find that, even at
high mupirocin concentrations, high numbers of organisms can survive for 120
hours and retain their ability to grow again in a manner similar to untreated cells,
when environmental conditions become favourable.
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Although the antibacterial properties of mupirocin support its use as a topical
antibiotic, we feel that, in some clinical applications (where high concentrations
of mupirocin locally challenge high numbers of staphylococci at a micro-
environment level), sufficient numbers ofviable organisms may remain to initiate
re-colonisation. This may explain the low percentage re-colonisation with the
same strain of staphylococcus seen in some studies.
The authors would like to thank Beecham Laboratories for supplies of mupirocin ointment, Professor
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marketed as Bactroban (Beecham), which is a 2% ointment in a water-miscible macrogel base.
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